Voriconazole treatment for less-common, emerging, or refractory fungal infections.

@article{Perfect2003VoriconazoleTF,
  title={Voriconazole treatment for less-common, emerging, or refractory fungal infections.},
  author={John R Perfect and Kieren A Marr and Thomas J Walsh and Richard Neil Greenberg and Bertrand Dupont and Juli{\'a}n de la Torre-Cisneros and Gudrun Just-Nuebling and Haran T. Schlamm and Irja Lutsar and A Espinel-ingroff and Elizabeth Edna Johnson},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2003},
  volume={36 9},
  pages={
          1122-31
        }
}
Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 253 CITATIONS

FILTER CITATIONS BY YEAR

2003
2018

CITATION STATISTICS

  • 15 Highly Influenced Citations

  • Averaged 8 Citations per year over the last 3 years

  • 67% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

  • R Ally, D Schurmann, W Kreisel
  • Clin Infect Dis
  • 2001
2 Excerpts

Similar Papers

Loading similar papers…